LigaChem collaborates with CStone on LCB71, showing efficacy in solid tumors and hematological cancers in global Phase 1 clinical trial

CAR-T Digest - August 2020

Weekly Digest - August 2024

27 Aug 2024: LigaChem collaborates with CStone on LCB71, showing efficacy in solid tumors and hematological cancers in global Phase 1 clinical trial

LigaChem Biosciences reported that its ROR1 ADC candidate, LCB71 (CS5001) demonstrated tolerance and safety in various solid and blood cancers during phase 1 trials in the U.S., Australia, and China
LCB71 is the first ROR1 ADC to show anticancer effects against solid tumors and lymphomas
LCB71 achieved an ORR of 55.6% for Hodgkin’s lymphoma in the fifth dose group (50μg/kg) and higher doses. Among nine patients, one achieved CR with tumor disappearance, while four others experienced PR
In the seventh dose group (100 μg/kg) and higher, LCB71 showed a 50% ORR for DLBCL, with one CR and two PRs among six patients. It also resulted in SD and PR in patients with NSCLC, pancreatic cancer, TNBC, and ovarian cancer

For full story click here